Codexis (CDXS) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Codexis Revenue Highlights

Latest Revenue (Y)

$70.14M

Latest Revenue (Q)

$12.83M

Main Segment (Y)

Enzyme Product

Main Geography (Y)

Asia Pacific

Codexis Revenue by Period

Codexis Revenue by Year

Date	Revenue	Change
2023-12-31	$70.14M	-49.39%
2022-12-31	$138.59M	32.30%
2021-12-31	$104.75M	51.69%
2020-12-31	$69.06M	0.87%
2019-12-31	$68.46M	12.98%
2018-12-31	$60.59M	21.13%
2017-12-31	$50.02M	2.43%
2016-12-31	$48.84M	16.82%
2015-12-31	$41.80M	18.40%
2014-12-31	$35.31M	10.60%
2013-12-31	$31.92M	-63.85%
2012-12-31	$88.30M	-28.71%
2011-12-31	$123.86M	15.65%
2010-12-31	$107.10M	29.18%
2009-12-31	$82.91M	64.25%
2008-12-31	$50.48M	99.26%
2007-12-31	$25.33M	108.90%
2006-12-31	$12.13M	-

Codexis generated $70.14M in revenue during NA 2023, up -49.39% compared to the previous quarter, and up 115.76% compared to the same period a year ago.

Codexis Revenue by Quarter

Date	Revenue	Change
2024-09-30	$12.83M	60.83%
2024-06-30	$7.98M	-53.27%
2024-03-31	$17.07M	-35.72%
2023-12-31	$26.56M	186.31%
2023-09-30	$9.28M	-56.49%
2023-06-30	$21.32M	64.25%
2023-03-31	$12.98M	-57.26%
2022-12-31	$30.38M	-11.88%
2022-09-30	$34.47M	-10.25%
2022-06-30	$38.41M	8.68%
2022-03-31	$35.34M	44.24%
2021-12-31	$24.50M	-33.37%
2021-09-30	$36.77M	44.46%
2021-06-30	$25.45M	41.15%
2021-03-31	$18.03M	-14.27%
2020-12-31	$21.03M	14.41%
2020-09-30	$18.39M	22.84%
2020-06-30	$14.97M	2.02%
2020-03-31	$14.67M	-21.34%
2019-12-31	$18.65M	-14.86%
2019-09-30	$21.91M	77.82%
2019-06-30	$12.32M	-20.95%
2019-03-31	$15.58M	-3.02%
2018-12-31	$16.07M	-5.18%
2018-09-30	$16.95M	25.17%
2018-06-30	$13.54M	-3.59%
2018-03-31	$14.04M	-35.36%
2017-12-31	$21.72M	117.57%
2017-09-30	$9.98M	-3.51%
2017-06-30	$10.35M	29.81%
2017-03-31	$7.97M	-20.04%
2016-12-31	$9.97M	-32.96%
2016-09-30	$14.87M	-7.07%
2016-06-30	$16.00M	100.13%
2016-03-31	$8.00M	-30.99%
2015-12-31	$11.59M	-33.42%
2015-09-30	$17.40M	189.15%
2015-06-30	$6.02M	-11.47%
2015-03-31	$6.80M	-52.10%
2014-12-31	$14.19M	89.92%
2014-09-30	$7.47M	13.73%
2014-06-30	$6.57M	-7.12%
2014-03-31	$7.07M	-25.73%
2013-12-31	$9.53M	141.57%
2013-09-30	$3.94M	-43.46%
2013-06-30	$6.97M	-39.26%
2013-03-31	$11.48M	45.11%
2012-12-31	$7.91M	-69.96%
2012-09-30	$26.34M	14.98%
2012-06-30	$22.91M	-26.42%
2012-03-31	$31.14M	-7.04%
2011-12-31	$33.49M	0.63%
2011-09-30	$33.28M	27.74%
2011-06-30	$26.05M	-16.04%
2011-03-31	$31.03M	4.10%
2010-12-31	$29.81M	9.95%
2010-09-30	$27.11M	10.76%
2010-06-30	$24.48M	-4.75%
2010-03-31	$25.70M	6.03%
2009-12-31	$24.24M	20.82%
2009-09-30	$20.06M	4.50%
2009-06-30	$19.20M	-1.09%
2009-03-31	$19.41M	4.37%
2008-12-31	$18.60M	122.09%
2008-03-31	$8.37M	78.02%
2007-03-31	$4.70M	-

Codexis generated $12.83M in revenue during Q3 2024, up 60.83% compared to the previous quarter, and up 60.18% compared to the same period a year ago.

Codexis Revenue Breakdown

Codexis Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Enzyme Product	$75.40M	$1.70M	-	-	-
Product Sales	$29.00M	$3.28M	$2.49M	$1.99M	$2.20M
Research and Development Revenue	$1.61M	$3.05M	$2.30M	$57.00K	$2.73M
Sitagliptin Enzyme	$1.60M	$2.80M	-	-	-
Service	-	$34.10M	$38.84M	$38.99M	$35.00M

Codexis's latest annual revenue breakdown by segment (product or service), as of Dec 22: Enzyme Product (70.07%), Product Sales (26.95%), Research and Development Revenue (1.50%), and Sitagliptin Enzyme (1.49%).

Quarterly Revenue by Product

Product/Service	Sep 24	Mar 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
Product	$11.16M	$18.68M	$19.10M	$8.37M	$3.60M	$2.50M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and Development Revenue	$1.68M	$3.88M	$1.54M	$7.50M	$7.08M	$1.47M	$2.33M	$2.10M	$7.52M	$3.36M	$3.50M	$1.98M	$8.82M	$2.07M	$2.21M	$6.48M	$13.77M	$1.29M	$5.57M	-
Product Sales	-	$10.49M	$21.38M	$3.05M	$2.97M	$16.98M	$2.84M	$1.98M	$2.82M	$12.21M	$1.99M	$2.83M	$2.05M	$4.88M	-	-	-	-	-	-
Research And Development Revenue	-	$7.52M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Enzyme Product	-	-	-	-	-	$19.80M	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Codexis's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (86.95%), and Research and Development Revenue (13.05%).

Codexis Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
EMEA	$56.54M	$20.19M	$19.26M	$37.13M	$22.36M
Americas	$17.00M	$23.48M	$24.35M	$13.04M	$15.37M
Asia Pacific	$65.05M	$61.09M	-	-	-
APAC	-	-	$25.45M	$18.29M	$22.86M

Codexis's latest annual revenue breakdown by geography, as of Dec 22: Asia Pacific (46.94%), EMEA (40.80%), and Americas (12.27%).

Quarterly Revenue by Country

Country	Sep 24	Mar 24	Sep 23	Dec 21	Sep 21	Dec 19	Jun 18	Mar 18
APAC	$9.07M	$7.26M	$1.81M	$2.77M	-	-	-	-
Americas	$1.53M	$7.24M	$4.28M	$3.42M	-	-	-	-
EMEA	$2.23M	$2.57M	$3.19M	$12.46M	$1.44M	$1.68M	-	-
Asia Pacific	-	-	-	$16.56M	$24.27M	-	-	-

Codexis's latest quarterly revenue breakdown by geography, as of Sep 24: APAC (70.68%), EMEA (17.37%), and Americas (11.95%).

Codexis Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
KYMR	Kymera Therapeutics	$78.59M	$3.74M
NRIX	Nurix Therapeutics	$76.99M	$12.59M
CDXS	Codexis	$70.14M	$12.83M
FHTX	Foghorn Therapeutics	$34.16M	$7.81M
RVMD	Revolution Medicines, Inc. Warrant	$11.58M	-
KZR	Kezar Life Sciences	$7.00M	-
GBIO	Generation Bio	$5.90M	$4.09M
IPSC	Century Therapeutics	$2.23M	$791.00K
STTK	Shattuck Labs	$1.66M	$1.61M
LYEL	Lyell Immunopharma	$130.00K	$34.00K
CGEM	Cullinan Oncology	-	-
NGM	NGM Biopharmaceuticals	-	$165.00K
NKTX	Nkarta	-	-
MLYS	Mineralys Therapeutics	-	-
GLUE	Monte Rosa Therapeutics	-	$4.70M
NUVB	Nuvation Bio	-	$727.00K

CDXS Revenue FAQ

What is Codexis’s yearly revenue?

Codexis's yearly revenue for 2023 was $70.14M, representing a decrease of -49.39% compared to 2022. The company's yearly revenue for 2022 was $138.59M, representing an increase of 32.30% compared to 2021. CDXS's yearly revenue for 2021 was $104.75M, representing an increase of 51.69% compared to 2020.

What is Codexis’s quarterly revenue?

Codexis's quarterly revenue for Q3 2024 was $12.83M, a 60.83% increase from the previous quarter (Q2 2024), and a 38.33% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $7.98M, a -53.27% decrease from the previous quarter (Q1 2024), and a -62.58% decrease year-over-year (Q2 2023). CDXS's quarterly revenue for Q1 2024 was $17.07M, a -35.72% decrease from the previous quarter (Q4 2023), and a 31.51% increase year-over-year (Q1 2023).

What is Codexis’s revenue growth rate?

Codexis's revenue growth rate for the last 3 years (2021-2023) was -33.04%, and for the last 5 years (2019-2023) was 2.46%.

What are Codexis’s revenue streams?

Codexis's revenue streams in c 22 are Enzyme Product, Product Sales, Research and Development Revenue, and Sitagliptin Enzyme. Enzyme Product generated $75.4M in revenue, accounting 70.07% of the company's total revenue, up 4335.29% year-over-year. Product Sales generated $29M in revenue, accounting 26.95% of the company's total revenue, up 783.75% year-over-year. Research and Development Revenue generated $1.61M in revenue, accounting 1.50% of the company's total revenue, down -47.18% year-over-year. Sitagliptin Enzyme generated $1.6M in revenue, accounting 1.49% of the company's total revenue, down -42.86% year-over-year.

What is Codexis’s main source of revenue?

For the fiscal year ending Dec 22, the largest source of revenue of Codexis was Enzyme Product. This segment made a revenue of $75.4M, representing 70.07% of the company's total revenue.